Otter. No we aren’t using iPS cells but we are keeping it proprietary at the moment as to what cells we intend to use.
yes it will be an autologous treatment but it will require special approval. The UK has one of the best regulatory positions. The approval that you mention is a “Marketing Approval” and there are exceptions here that allow clinicians to provide treatments to patients under special circumstances that can happen without a marketing license. Obviously treatments wouldn’t be offered by clinicians until they were convinced as to their efficacy.